Home Nav
Nextech Invest Logo

Jakob Loven

Alfred Scheidegger

Jakob Loven, Ph.D., joined Nextech Invest as Partner in 2017 from Third Rock Ventures, where Jakob focused on new company formation in the areas of oncology and emerging technologies. Dr. Loven also served on the firm’s scientific ideation team, overseeing several early-stage projects and leading efforts to transform emerging areas of science into innovative drug discovery companies with unique scientific platforms. Jakob brings to Nextech the passion of a serial entrepreneur. While at Third Rock, Jakob launched Relay Therapeutics in Cambridge Massachusetts, which was selected as one of Fiercebiotech’s Fierce 15 in 2017. Prior to Relay, Jakob was a Founding Scientist of Syros Pharmaceuticals (NASDAQ: SYRS), which was founded on his co-discoveries in gene regulation sciences and technologies, and had its initial public offering in July 2016. Jakob holds a BA in Biomedical Sciences from the Anglia Ruskin University of Cambridge, earned his Ph.D. in Medical Sciences from Karolinska Institutet, and conducted his postdoctoral fellowship at the Whitehead Institute for Biomedical Research. During his appointment at the Whitehead Institute, Jakob pioneered the field of gene regulation research through numerous scientific findings, authoring several high-impact journal articles. At Nextech, Jakob manages our investments in Autolus, A2 Biotherapeutics, Arvinas and Turning Point Therapeutics.

Mr. Loven is responsible for the following Nextech portfolio companies:

Turning Point Therapeutics, Arvinas, A2 Biotherapeutics

Portfolio companies Mr. Loven has been involved with previously:



Personalized Oncology 2019 conference

23.06. – 25.06.2019

Basel, Switzerland

  • 24.07.2019

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives...

  • 18.07.2019

    Blueprint Medicines Announces European Medicines Agency...

  • 15.07.2019

    Neon Therapeutics ’ Personal Neoantigen Vaccine Study...


Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.


* Compulsory fields


Newsletter Registration

Your eMail have been successfully registered.